Skip to main content
SpringerLink
Log in

A phase II trial of oral temozolomide in patients with metastatic renal cell cancer

  • Clinical Trial Report
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Heading

Abstract

Purpose. To determine the activity of temozolomide, an oral imidazotetrazine alkylating agent that has exhibited broad antitumor activity in preclinical studies, in renal cell cancer (RCC) patients.

Methods. Metastatic RCC patients were treated with temozolomide, 200 mg/m2 per day orally, and traditional radiologic response endpoints were assessed. O6-Alkylguanine-DNA alkyltransferase (AGT) activity was measured in four pretreatment biopsies.

Results. Among 12 patients, there were no responses. High AGT activity was observed in all four biopsies analyzed.

Conclusions. Temozolomide is not active against RCC and this clinical observation may be due to high levels of AGT in this tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Department of Medicine, University of Chicago, Chicago, IL 60637, USA, , , , ,

    D. Park

  2. Section Hematology/Oncology, Department of Medicine, Cancer Research Center, University of Chicago, 5841S. Maryland Ave., MC 2115, Chicago, IL 60637, USA, , , , ,

    C. Ryan,  M. Dolan,  N. Vogelzang &  W. Stadler

Authors
  1. D. Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Dolan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Vogelzang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W. Stadler
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Electronic Publication

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, .D., Ryan, .C., Dolan, .M. et al. A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol 50, 160–162 (2002). https://doi.org/10.1007/s00280-002-0473-z

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-002-0473-z

Search

Navigation